[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR097973A1 - FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO - Google Patents

FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO

Info

Publication number
AR097973A1
AR097973A1 ARP140103761A ARP140103761A AR097973A1 AR 097973 A1 AR097973 A1 AR 097973A1 AR P140103761 A ARP140103761 A AR P140103761A AR P140103761 A ARP140103761 A AR P140103761A AR 097973 A1 AR097973 A1 AR 097973A1
Authority
AR
Argentina
Prior art keywords
gnrh
pharmaceutical formulation
gonadotropine
agonist
treatment method
Prior art date
Application number
ARP140103761A
Other languages
English (en)
Inventor
Charles Joseph Schwach Gregoire
Andrew Whitaker Mark
John ARROWSMITH Nicholas
Naylor Andrew
SCHIEFELBEIN Lars
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR097973A1 publication Critical patent/AR097973A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica que comprende una matriz sólida de uno o más polímeros biodegradables, la matriz sólida que incluye un principio farmacéuticamente activo o una de sus sales aceptables desde el punto de vista farmacéutico distribuidos en forma homogénea o en forma sustancialmente homogénea dentro de la matriz; en donde el principio farmacéuticamente activo es hormona liberadora de gonadotropina (GnRH), un agonista de GnRH o un antagonista de GnRH. Reivindicación 2: Una formulación farmacéutica de acuerdo con la reivindicación 1 en donde el principio farmacéuticamente activo es degarelix. Reivindicación 7: Una formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones que anteceden en donde el (o cada) polímero biodegradable es un copolímero de ácido láctico y glicólico (PLGA).
ARP140103761A 2013-10-08 2014-10-08 FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO AR097973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13187665 2013-10-08

Publications (1)

Publication Number Publication Date
AR097973A1 true AR097973A1 (es) 2016-04-20

Family

ID=49303859

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103761A AR097973A1 (es) 2013-10-08 2014-10-08 FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO

Country Status (13)

Country Link
US (1) US10441626B2 (es)
EP (1) EP3054968A1 (es)
JP (1) JP6534994B2 (es)
KR (1) KR20160065968A (es)
CN (1) CN105792838A (es)
AR (1) AR097973A1 (es)
AU (1) AU2014333911A1 (es)
CA (1) CA2926358A1 (es)
IL (1) IL244911A0 (es)
MX (1) MX2016004444A (es)
RU (1) RU2016114805A (es)
TW (1) TW201601744A (es)
WO (1) WO2015052204A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987081C (en) * 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CA2986456A1 (en) * 2015-07-09 2017-01-12 Evonik Rohm Gmbh Process for preparing poly(glycolide-co-lactide) copolymer microparticles
DE102015226456A1 (de) * 2015-12-22 2017-06-22 Heraeus Medical Gmbh Verfahren zur Sterilisation von wässrigen Polysaccharidlösungen und sterile wässrige Polysaccharidlösungen
EP3852729A4 (en) * 2018-09-20 2022-07-06 Biovena Science, LLC ARTERIAL EMBOLIZATION BASED ON FLUTAMIDE MICROSPHERES FOR THE TREATMENT OF PROSTATE DISORDERS
US20220062177A1 (en) * 2018-10-02 2022-03-03 InnoCore Technologies Holding B.V. Extended release formulations of human chorionic gonadotropin (hcg)
CN112956699A (zh) * 2021-01-27 2021-06-15 上海海洋大学 一种降血糖肽肠溶固体分散体及其制备方法
KR102386163B1 (ko) * 2021-12-03 2022-04-14 (주)인벤티지랩 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법
TW202432169A (zh) * 2023-02-10 2024-08-16 美商托馬股份有限公司 輔美康（degarelix）有機溶劑調配物
WO2024168022A2 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH679207A5 (es) * 1989-07-28 1992-01-15 Debiopharm Sa
CA2582666C (en) * 1994-04-08 2010-05-25 Qlt Usa, Inc. Controlled release implant
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
KR100453273B1 (ko) * 2003-09-04 2004-10-15 주식회사 펩트론 초음파 이중공급노즐을 이용한 서방성 미립구의 제조 방법
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
JP3839839B2 (ja) 2004-06-25 2006-11-01 株式会社セブンスディメンジョンデザイン 医療画像管理システム及び医療画像管理方法
US8329863B2 (en) * 2004-07-16 2012-12-11 Oakwood Laboratories, Llc Gonadotropin releasing hormone antagonists
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.

Also Published As

Publication number Publication date
MX2016004444A (es) 2016-11-10
TW201601744A (zh) 2016-01-16
WO2015052204A1 (en) 2015-04-16
US20160228494A1 (en) 2016-08-11
JP2016534040A (ja) 2016-11-04
KR20160065968A (ko) 2016-06-09
EP3054968A1 (en) 2016-08-17
CA2926358A1 (en) 2015-04-16
RU2016114805A3 (es) 2018-07-11
IL244911A0 (en) 2016-05-31
CN105792838A (zh) 2016-07-20
US10441626B2 (en) 2019-10-15
AU2014333911A1 (en) 2016-05-05
RU2016114805A (ru) 2017-11-15
JP6534994B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
AR097973A1 (es) FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO
CY1124037T1 (el) Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
PE20171308A1 (es) Forma de dosificacion que incluye una solucion solida de drogas amorfas
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CO7160109A2 (es) Formulación de implantes de paliperidona
AR104212A1 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
BR112016007414A2 (pt) método de produção de um comprimido de monocamada, e, comprimido de monocamada
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
UA118576C2 (uk) Фармацевтична композиція, яка містить бринзоламід
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
CO2017005578A2 (es) Unidad de dispositivo de droga que contiene quinagolida
AR096223A1 (es) Pastilla de nicotina para administración oral
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
AR093922A1 (es) Composicion farmaceutica que contiene telmisartan
CY1120749T1 (el) Φαρμακευτικες δοσολογικες μορφες
AR103188A1 (es) Formulaciones de paracetamol inyectables
CL2015003702A1 (es) Formulación farmacéutica en forma de micropartículas estériles, que comprenden como agente activo rhein, y copolímeros del ácido láctico y glicólico (plga). proceso de elaboración y uso en pacientes que presentan patologías articulares.

Legal Events

Date Code Title Description
FB Suspension of granting procedure